Free Trial
NYSEAMERICAN:DSS

DSS Q2 2023 Earnings Report

DSS logo
$0.94 -0.06 (-6.00%)
As of 05/6/2025 04:10 PM Eastern

DSS EPS Results

Actual EPS
-$1.40
Consensus EPS
-$0.40
Beat/Miss
Missed by -$1.00
One Year Ago EPS
N/A

DSS Revenue Results

Actual Revenue
$7.23 million
Expected Revenue
$9.94 million
Beat/Miss
Missed by -$2.71 million
YoY Revenue Growth
N/A

DSS Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Monday, August 14, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

DSS' Q1 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

DSS Earnings Headlines

Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.
See More DSS Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like DSS? Sign up for Earnings360's daily newsletter to receive timely earnings updates on DSS and other key companies, straight to your email.

About DSS

DSS (NYSEAMERICAN:DSS) operates in the product packaging, biotechnology, commercial lending, securities and investment management, alternative trading, and direct marketing businesses. It manufactures, markets, and sells mailers, photo sleeves, custom folding cartons, and 3-dimensional direct mail solutions; and markets and distributes nutritional and personal care products. The company also invests in or acquires companies in the biohealth and biomedical fields, including businesses that focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases; and develops open-air defense initiatives for air-borne infectious diseases comprising tuberculosis and influenza. In addition, it focuses on acquiring equity positions in undervalued commercial banks, bank holding companies, and nonbanking licensed financial companies; and companies engages in nonbanking activities related to banking, such as loan syndication, mortgage banking, trust and escrow, banking technology, loan servicing, equipment leasing, problem asset management, special purpose acquisition company consulting, and advisory capital raising services. Further, the company provides securities and investment management services; and operates a real estate investment trust for acquiring hospitals and other acute or post-acute care centers. Additionally, it develops and/or acquires assets and investments in the securities trading and/or funds management arena, as well as operates as a digital assets broker dealer. The company was formerly known as Document Security Systems, Inc. and changed its name to DSS, Inc. in September 2021. DSS, Inc. was incorporated in 1984 and is headquartered in West Henrietta, New York.

View DSS Profile

More Earnings Resources from MarketBeat